Stockscreener 앱 받기
37.95
0.85%
-0.3328
전일 마감가:
$38.28
열려 있는:
$38.28
하루 거래량:
485.91K
Relative Volume:
0.77
시가총액:
$2.81B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-13.85
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+0.30%
1개월 성능:
+29.10%
6개월 성능:
-12.40%
1년 성능:
-13.25%
1일 변동 폭
$37.55
$38.47
1주일 범위
$36.94
$39.01
52주 변동 폭
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
37.94 | 2.81B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.01 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.78 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.28 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.91 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
(XENE) On The My Stocks Page - news.stocktradersdaily.com
Renaissance Technologies LLC Decreases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE Stock News - GuruFocus
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Expands Team with $3M Equity Package: 78,600 Options Granted to New Hires - Stock Titan
This trade activity should not be overlooked: Xenon Pharmaceuticals Inc (XENE) - Sete News
Upward Trajectory: Xenon Pharmaceuticals Inc (XENE) Posts a Slidee, Closing at 38.20 - DWinneX
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc [XENE] MORTIMER IAN sells 22,468 Shares for $0.9 million - knoxdaily.com
Geode Capital Management LLC Purchases 720 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Envestnet Asset Management Inc. Sells 1,539 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Xenon Pharmaceuticals Inc (NASDAQ:XENE)’s 12-Month Price Target Currently Stands At 42 - Marketing Sentinel
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Wells Fargo & Company MN Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
Market Insights: Xenon Pharmaceuticals Inc (XENE)’s Notable Gain of 2.34, Closing at 37.59 - DWinneX
Xenon Pharmaceuticals Inc (XENE) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Hold Rating - Defense World
When (XENE) Moves Investors should Listen - news.stocktradersdaily.com
The Goldman Sachs Group Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price - Defense World
Xenon- A Later Stage Story (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Q1 EPS Forecast for Xenon Pharmaceuticals Raised by Analyst - Defense World
Xenon Pharmaceuticals: Undervalued Stock with Promising Catalysts and Growth Potential - TipRanks
StockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Sell - Defense World
XENE stock touches 52-week low at $28.51 amid market shifts By Investing.com - Investing.com South Africa
XENE stock touches 52-week low at $28.51 amid market shifts - Investing.com
JPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Prudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Raymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025 - TipRanks
Xenon Slides Ahead of San Diego Concference - Baystreet.ca
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 - The Manila Times
Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data - Stock Titan
Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq
Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xenon Pharmaceuticals Inc 주식 (XENE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
0.27%
0.30%
자본화:
|
볼륨(24시간):